Evidences for a progressive microglial activation and increase in iNOS expression in rats submitted to a neurodevelopmental model of schizophrenia: Reversal by clozapine

Schizophrenia Research

Volumn 151, Issue 1-3, 2013, Pages 12-19

  Ribeiro, Bruna Mara Machado ^a   do Carmo, Marta Regina Santos ^a   Freire, Rosemayre Souza ^a   Rocha, Nayrton Flávio Moura ^a   Borella, Vládia Célia Moreira ^a   de Menezes, Antonio Teles ^a   Monte, Aline Santos ^a   Gomes, Patrícia Xavier Lima ^a   de Sousa, Francisca Cléa Florenço ^a   Vale, Mariana Lima ^a   de Lucena, David Freitas ^a   Gama, Clarissa Severino ^b   Macêdo, Danielle ^a  

^a FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

Clozapine; Neonate; Neuroinflammation; Neuroprogression; PolyI:C; Schizophrenia

Indexed keywords

CELL MARKER; CELL PROTEIN; CLOZAPINE; GLUTATHIONE; INDUCIBLE NITRIC OXIDE SYNTHASE; LIPID; MALONALDEHYDE; PROTEIN IBA 1; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL ACTIVATION; CELL MATURATION; CONTROLLED STUDY; CORPUS STRIATUM; DEGENERATIVE DISEASE; DISEASE COURSE; HIPPOCAMPAL CA2 REGION; HIPPOCAMPAL CA3 REGION; INFLAMMATION; LIPID PEROXIDATION; MALE; MAZE TEST; MEMORY DISORDER; MICROGLIA; NERVE DEGENERATION; NEWBORN; NONHUMAN; OXIDATIVE STRESS; PREFRONTAL CORTEX; PREPULSE INHIBITION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SCHIZOPHRENIA; STARTLE REFLEX; TASK PERFORMANCE; WORKING MEMORY; YOUNG ADULT;

CLOZAPINE; NEONATE; NEUROINFLAMMATION; NEUROPROGRESSION; POLYI:C; SCHIZOPHRENIA;

AGE FACTORS; ANIMALS; ANIMALS, NEWBORN; ANTIPSYCHOTIC AGENTS; BRAIN; CLOZAPINE; DEVELOPMENTAL DISABILITIES; DISEASE MODELS, ANIMAL; LIPID PEROXIDATION; MALE; MALONDIALDEHYDE; MAZE LEARNING; MICROGLIA; NITRIC OXIDE SYNTHASE TYPE II; OXIDATIVE STRESS; POLY I-C; RATS; RATS, WISTAR; SCHIZOPHRENIA; STARTLE REACTION;

EID: 84889092626     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2013.10.040     Document Type: Article

References (56)

1. Ahmed Z., Shaw G., Sharma V.P., Yang C., McGowan E., Dickson D.W. Actin-binding proteins Coronin-1a and IBA-1 are effective microglial markers for immunohistochemistry. J. Histochem. Cytochem. 2007, 55(7):687-700.
2. Amann L.C., Gandal M.J., Halene T.B., Ehrlichman R.S., White S.L., McCarren H.S., Siegel S.J. Mouse behavioral endophenotypes for schizophrenia. Brain Res. Bull. 2010, 83(3-4):147-161.
3. Andersen S.L. Trajectories of brain development: point of vulnerability or window of opportunity?. Neurosci. Biobehav. Rev. 2003, 27(1-2):3-18.
4. Anderson G., Berk M., Dodd S., Bechter K., Altamura A.C., Dell'Osso B., Kanba S., Monji A., Fatemi S.H., Buckley P., Debnath M., Das U.N., Meyer U., Müller N., Kanchanatawan B., Maes M. Immuno-inflammatory, oxidative and nitrosative stress, and neuroprogressive pathways in the etiology, course and treatment of schizophrenia. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2013, 42:1-4.
5. Basta-Kaim A., Szczesny E., Leskiewicz M., Glombik K., Slusarczyk J., Budziszewska B., Regulska M., Kubera M., Nowak W., Wedzony K., Lason W. Maternal immune activation leads to age-related behavioral and immunological changes in male rat offspring - the effect of antipsychotic drugs. Pharmacol. Rep. 2012, 64(6):1400-1410.
6. Bayer T.A., Buslei R., Havas L., Falkai P. Evidence for activation of microglia in patients with psychiatric illnesses. Neurosci. Lett. 1999, 271(2):126-128.
7. Bernstein H.G., Bogerts B., Keilhoff G. The many faces of nitric oxide in schizophrenia. A review. Schizophr. Res. 2005, 78(1):69-86.
8. Bilbo S.D., Schwarz J.M. Early-life programming of later-life brain and behavior: a critical role for the immune system. Front. Behav. Neurosci. 2009, 3(14):24.
9. Bitanihirwe B.K.Y., Woo T.-U.W. Oxidative stress in schizophrenia: an integrated approach. Neurosci. Biobehav. Rev. 2011, 35(3):878-893.
10. Borutaite V., Budriunaite A., Brown G.C. Reversal of nitric oxide-, peroxynitrite- and S-nitrosothiol-induced inhibition of mitochondrial respiration or complex I activity by light and thiols. Biochim. Biophys. Acta 2000, 15:2-3.
11. Brown, V., 1996. The rat nervous system: (2nd edn.) Edited by George Paxinos. Academic Press, Sydney, 1995. Neuropsychologia 34(2), 160.
12. Brown G., Neher J. Inflammatory neurodegeneration and mechanisms of microglial killing of neurons. Mol. Neurobiol. 2010, 41(2-3):242-247.
13. Chaudhry I.B., Hallak J., Husain N., Minhas F., Stirling J., Richardson P., Dursun S., Dunn G., Deakin B. Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment. J. Psychopharmacol. 2012, 26(9):1185-1193.
14. Clancy B., Darlington R.B., Finlay B.L. Translating developmental time across mammalian species. Neuroscience 2001, 105(1):7-17.
15. Clancy B., Finlay B.L., Darlington R.B., Anand K.J. Extrapolating brain development from experimental species to humans. Neurotoxicology 2007, 28(5):931-937.
16. Conrad C.D., Galea L.A.M., Kuroda Y., McEwen B.S. Chronic stress impairs rat spatial memory on the Y maze, and this effect is blocked by tianeptine treatment. Behav. Neurosci. 1996, 110(6):1321-1334.
17. Dall'Igna O.P., Fett P., Gomes M.W., Souza D.O., Cunha R.A., Lara D.R. Caffeine and adenosine A(2a) receptor antagonists prevent beta-amyloid (25-35)-induced cognitive deficits in mice. Exp. Neurol. 2007, 203(1):241-245.
18. Dean O., Bush A.I., Berk M., Copolov D.L., van den Buuse M. Interaction of glutathione depletion and psychotropic drug treatment in prepulse inhibition in rats and mice. Pharmacol. Biochem. Behav. 2010, 97(2):293-300.
19. Floresco S.B., Braaksma D.N., Phillips A.G. Thalamic-cortical-striatal circuitry subserves working memory during delayed responding on a radial arm maze. J. Neurosci. 1999, 19(24):11061-11071.
20. Ganzinelli S., Borda E., Sterin-Borda L. Autoantibodies from schizophrenia patients induce cerebral cox-1/iNOS mRNA expression with NO/PGE2/MMP-3 production. Int. J. Neuropsychopharmacol. 2010, 13(3):293-303.
21. Greenwood T.A., Braff D.L., Light G.A., et al. Initial heritability analyses of endophenotypic measures for schizophrenia: the consortium on the genetics of schizophrenia. Arch. Gen. Psychiatry 2007, 64(11):1242-1250.
22. Gupta S., Kulhara P. What is schizophrenia: a neurodevelopmental or neurodegenerative disorder or a combination of both? A critical analysis. Indian J. Psychiatry 2010, 52(1):21-27.
23. Hallak J.E., Maia-de-Oliveira J.P., Abrao J., Evora P.R., Zuardi A.W., Crippa J.A., Belmonte-de-Abreu P., Baker G.B., Dursun S.M. Rapid improvement of acute schizophrenia symptoms after intravenous sodium nitroprusside: a randomized, double-blind, placebo-controlled trial. JAMA Psychiatry 2013, 70(7):668-676.
24. Herken H., Uz E., Ozyurt H., Akyol O. Red blood cell nitric oxide levels in patients with schizophrenia. Schizophr. Res. 2001, 52(3):289-290. (Dec 1).
25. Hu X., Zhou H., Zhang D., Yang S., Qian L., Wu H.M., Chen P.S., Wilson B., Gao H.M., Lu R.B., Hong J.S. Clozapine protects dopaminergic neurons from inflammation-induced damage by inhibiting microglial overactivation. J. Neuroimmune Pharmacol. 2012, 7(1):187-201.
26. Ibi D., Nagai T., Kitahara Y., Mizoguchi H., Koike H., Shiraki A., Takuma K., Kamei H., Noda Y., Nitta A., Nabeshima T., Yoneda Y., Yamada K. Neonatal polyI:C treatment in mice results in schizophrenia-like behavioral and neurochemical abnormalities in adulthood. Neurosci. Res. 2009, 64(3):297-305.
27. Juckel G., Manitz M.P., Brune M., Friebe A., Heneka M.T., Wolf R.J. Microglial activation in a neuroinflammational animal model of schizophrenia-a pilot study. Schizophr. Res. 2011, 131(1-3):96-100.
28. Lalonde R. The neurobiological basis of spontaneous alternation. Neurosci. Biobehav. Rev. 2002, 26(1):91-104.
29. Le Pen G., Moreau J.L. Disruption of prepulse inhibition of startle reflex in a neurodevelopmental model of schizophrenia: reversal by clozapine, olanzapine and risperidone but not by haloperidol. Neuropsychopharmacology 2002, 27(1):1-11.
30. Levin R., Calzavara M.B., Santos C.M., Medrano W.A., Niigaki S.T., Abilio V.C. Spontaneously hypertensive rats (SHR) present deficits in prepulse inhibition of startle specifically reverted by clozapine. Prog. Neuropsychopharmacol. Biol. Psychiatry 2011, 35(7):1748-1752.
31. Lipska B.K., Weinberger D.R. A neurodevelopmental model of schizophrenia: neonatal disconnection of the hippocampus. Neurotox. Res. 2002, 4(5-6):469-475.
32. Maes M., Bocchio Chiavetto L., Bignotti S., Battisa Tura G.-J., Pioli R., Boin F., Kenis G., Bosmans E., de Jongh R., Altamura C.A. Increased serum interleukin-8 and interleukin-10 in schizophrenic patients resistant to treatment with neuroleptics and the stimulatory effects of clozapine on serum leukemia inhibitory factor receptor. Schizophr. Res. 2002, 54(3):281-291.
33. Martins M.R., Petronilho F.C., Gomes K.M., Dal-Pizzol F., Streck E.L., Quevedo J. Antipsychotic-induced oxidative stress in rat brain. Neurotox. Res. 2008, 13(1):63-69.
34. Maynard T.M., Sikich L., Lieberman J.A., LaMantia A.S. Neural development, cell-cell signaling, and the "two-hit" hypothesis of schizophrenia. Schizophr. Bull. 2001, 27(3):457-476.
35. McAllister C.G., van Kammen D.P., Rehn T.J., Miller A.L., Gurklis J., Kelley M.E., Yao J., Peters J.L. Increases in CSF levels of interleukin-2 in schizophrenia: effects of recurrence of psychosis and medication status. Am. J. Psychiatry 1995, 152(9):1291-1297.
36. McDonald C., Murray R.M. Early and late environmental risk factors for schizophrenia. Brain Res. Brain Res. Rev. 2000, 31(2-3):130-137.
37. Meyer U. Prenatal poly(I:C) exposure and other developmental immune activation models in rodent systems. Biol. Psychiatry 2013, 9(13). (00638-00630) (in press).
38. Monji A., Kato T., Kanba S. Cytokines and schizophrenia: microglia hypothesis of schizophrenia. Psychiatry Clin. Neurosci. 2009, 63(3):257-265.
39. Monji A., Kato T.A., Mizoguchi Y., Horikawa H., Seki Y., Kasai M., Yamauchi Y., Yamada S., Kanba S. Neuroinflammation in schizophrenia especially focused on the role of microglia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2013, 42:115-121.
40. Ohkawa H., Ohishi N., Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal. Biochem. 1979, 95(2):351-358.
41. Pozzi S., Benedusi V., Maggi A., Vegeto E. Estrogen action in neuroprotection and brain inflammation. Ann. N. Y. Acad. Sci. 2006, 1089(1):302-323.
42. Radewicz K., Garey L.J., Gentleman S.M., Reynolds R. Increase in HLA-DR immunoreactive microglia in frontal and temporal cortex of chronic schizophrenics. J. Neuropathol. Exp. Neurol. 2000, 59(2):137-150.
43. Reagan-Shaw S., Nihal M., Ahmad N. Dose translation from animal to human studies revisited. FASEB J. 2008, 22(3):659-661.
44. Romero E., Guaza C., Castellano B., Borrell J. Ontogeny of sensorimotor gating and immune impairment induced by prenatal immune challenge in rats: implications for the etiopathology of schizophrenia. Mol. Psychiatry 2010, 15(4):372-383.
45. Sedlak J., Lindsay R.H. Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman's reagent. Anal. Biochem. 1968, 25(1):192-205.
46. Srivastava N., Barthwal M.K., Dalal P.K., Agarwal A.K., Nag D., Srimal R.C., Seth P.K., Dikshit M. Nitrite content and antioxidant enzyme levels in the blood of schizophrenia patients. Psychopharmacology 2001, 158(2):140-145.
47. Steinert J.R., Chernova T., Forsythe I.D. Nitric oxide signaling in brain function, dysfunction, and dementia. Neuroscientist 2010, 16(4):435-452.
48. Sugino H., Futamura T., Mitsumoto Y., Maeda K., Marunaka Y. Atypical antipsychotics suppress production of proinflammatory cytokines and up-regulate interleukin-10 in lipopolysaccharide-treated mice. Prog. Neuropsychopharmacol. Biol. Psychiatry 2009, 33(2):303-307.
49. Swerdlow N.R., Geyer M.A. Using an animal model of deficient sensorimotor gating to study the pathophysiology and new treatments of schizophrenia. Schizophr. Bull. 1998, 24(2):285-301.
50. Swerdlow N.R., Geyer M.A., Braff D.L. Neural circuit regulation of prepulse inhibition of startle in the rat: current knowledge and future challenges. Psychopharmacology 2001, 156(2-3):194-215.
51. Theodoropoulou S., Spanakos G., Baxevanis C.N., Economou M., Gritzapis A.D., Papamichail M.P., Stefanis C.N. Cytokine serum levels, autologous mixed lymphocyte reaction and surface marker analysis in never medicated and chronically medicated schizophrenic patients. Schizophr. Res. 2001, 47(1):13-25.
52. van Berckel B.N., Bossong M.G., Boellaard R., Kloet R., Schuitemaker A., Caspers E., Luurtsema G., Windhorst A.D., Cahn W., Lammertsma A.A., Kahn R.S. Microglia activation in recent-onset schizophrenia: a quantitative (R)-[11C]PK11195 positron emission tomography study. Biol. Psychiatry 2008, 64(9):820-822.
53. Weinberger D.R. Implications of normal brain development for the pathogenesis of schizophrenia. Arch. Gen. Psychiatry 1987, 44(7):660-669.
54. Williams S.M., Diaz C.M., Macnab L.T., Sullivan R.K.P., Pow D.V. Immunocytochemical analysis of D-serine distribution in the mammalian brain reveals novel anatomical compartmentalizations in glia and neurons. Glia 2006, 53(4):401-411.
55. Woods B.T. Is schizophrenia a progressive neurodevelopmental disorder? Toward a unitary pathogenetic mechanism. Am. J. Psychiatry 1998, 155(12):1661-1670.
56. Yamada K., Noda Y., Hasegawa T., Komori Y., Nikai T., Sugihara H., Nabeshima T. The role of nitric oxide in dizocilpine-induced impairment of spontaneous alternation behavior in mice. J. Pharmacol. Exp. Ther. 1996, 276(2):460-466.